Home › Epilepsy › NCT07116421
Effect of Rose Odor Exposure on Ictal Apnea
Effect of 2-phenylethanol Odor Exposure on Ictal Apneic Episode Occurrence Rate in Patients With Epilepsy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult epilepsy patients over the age of 18 * Admission to the inpatient epilepsy monitoring unit (EMU) at Vanderbilt University Medical Center (VUMC) * Undergoing observational EEG monitoring without treatment involving seizure medication changes or other interventions for at least 48 hours Exclusion Criteria: * Patients under the age of 18 * Patients receiving EEG monitoring without interventions from baseline for less than 48 hours * Patients who are not receiving EEG monitoring as a part of their inpatient admission.
About the study
This study will investigate the potential benefits of rose scent in reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP) in patients with epilepsy. Participants will engage in their routine inpatient observational EEG monitoring for 24 hours followed by an additional 24 hours of observational EEG monitoring with continuous exposure to rose scent, during which an essential oil diffusor with rose scent will be placed in their hospital room. During these 48 total hours of the study, participants will wear a respiratory monitoring belt across their upper chest to measure their breathing.
Potential risks include distress or discomfort when smelling the rose scent used in the study, a physical reaction to the rose scent, and discomfort or feelings of restrictiveness when wearing the respiratory monitoring belt. The total time commitment of the study is 48 consecutive hours over the course of the participants' inpatient EMU stay, during which there will be no restrictions on daily activities during the standard inpatient EMU admission except that participants must wear their respiratory belt for a majority of this 2-day period.
What is being tested
- 2-phenylethanol rose scent (drug)
Sponsor: Vanderbilt University Medical Center · Participants: 40 · Started: Jul 1, 2025
Contact the study team
- Brigitte Jia, BA · Phone: 925-378-9234
- William P Nobis, MD, PhD · Phone: 615-936-5776
Official record on ClinicalTrials.gov — NCT07116421
Locations in the U.S.
| Tennessee | Vanderbilt University Medical Center, Nashville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.